Transaction details
On March 16, 2026, Jason Eric Evans, Chief Executive Officer of Surgery Partners (NASDAQ: SGRY), sold 20,400 shares of the company's common stock at $12.47 per share, for total proceeds of $254,388. Following the sale, Evans directly holds 920,386 shares of Surgery Partners.
The company's share price has been under pressure: the stock was trading near its 52-week low of $12.25 and, as of the most recent quote cited in this report, was at $12.39, down 49% over the past year.
Purpose of the sale
The CEO said the disposition was executed to satisfy tax withholding obligations related to restricted stock that vested on March 4, 2026. The sale, therefore, was not described as a discretionary liquidity event separate from a tax requirement tied to equity compensation.
Analyst and market context
Surgery Partners, a company with a market value of $1.59 billion, has attracted attention from Wall Street amid recent operational and strategic developments. According to InvestingPro, analysts expect the company to be profitable this year, and InvestingPro offers six additional exclusive tips for SGRY investors.
RBC Capital has reduced its price target for Surgery Partners to $20 from $31, explicitly citing softer-than-anticipated guidance for 2026. That guidance was noted to exclude expected mergers and acquisitions, which RBC says affected its outlook.
TD Cowen also trimmed its price target to $20 from $28 but maintained a Buy rating. TD Cowen attributed its adjustment to the company's adjusted EBITDA-NCI results coming in 6% below consensus estimates, a shortfall driven by a negative insurance mix shift and specific market-level issues.
UBS reiterated a Buy rating with a $21 price target in the wake of activism from Ortelius Advisors. In an open letter to shareholders, the hedge fund urged steps including the monetization of surgical hospitals and a review of strategic alternatives.
Governance move
Separately, Surgery Partners appointed Lloyd Dean, the former CEO of CommonSpirit Health, to its Board of Directors. The addition comes amid the activist campaign and the company's broader strategic reassessment.
These developments - insider stock activity tied to equity vesting, analyst target cuts driven by guidance and EBITDA dynamics, activist proposals on asset monetization, and a new board appointment - together underscore a period of strategic reassessment and leadership transition for Surgery Partners.